Second-Generation Anti-Cancer Vaccine Targets Melanoma
Defence Therapeutics Inc. has announced the successful testing of a second-generation anti-cancer vaccine, ARM-002TM, using its lead anti-cancer molecule AccuTOX®. The vaccine led to an 80% complete response when combined with the anti-PD-1 immune checkpoint inhibitor in a melanoma cancer model. This breakthrough in cancer treatment is expected to have a significant impact on the industry, with the vaccine segment projected to reach revenues of about $900 billion by 2029.
Study Finds Micro- and Nanoplastics Passed on During Cell Division
A recent study reveals that micro- and nanoplastic particles persist in the human body and are transmitted to newly formed cells during division, potentially enhancing tumor metastasis. The findings, published in ‘Chemospheres’, highlight the effects of plastic particles on cancer cells in the gastrointestinal tract.
Enobosarm Shows Promising Antitumor Activity in ER-Positive, HER2-Negative Advanced Breast Cancer
A recent study published in The Lancet Oncology has shown promising antitumor activity of enobosarm in patients with ER-positive, HER2-negative advanced breast cancer. The study assessed the activity and safety of enobosarm in women with previously treated locally advanced or metastatic breast cancer, with results showing potential benefits but also some drug-related adverse events. The study was funded by GTx, the original developer of enobosarm, and has implications for the potential role of androgen receptor modulation in cancer therapy.
Enzyme Checkpoint Identified in Tumor-Associated Macrophages
A recent study has identified an enzyme, phosphoglycerate dehydrogenase (PHGDH), as a metabolic checkpoint in the function of tumor-associated macrophages (TAMs), affecting tumor growth. Targeting PHGDH could be a new approach in cancer treatment, potentially improving the effectiveness of clinical immunotherapies. The study utilized innovative methods, including AI and machine learning, to diagnose metabolic markers and identify checkpoints, leading to the discovery of the metabolic checkpoint in macrophage polarization.
Study Reveals Potential Link Between Chronic Stress and Cancer Metastasis
A recent study from Cold Spring Harbor Laboratory Cancer Center has revealed a potential link between stress and cancer metastasis, paving the way for new treatment strategies. Chronic stress has long been known to have detrimental effects on health, increasing the risk of conditions such as heart disease, strokes, and potentially aiding in the spread of cancer. The study found that stress induces the formation of sticky web-like structures by certain white blood cells, rendering body tissues more susceptible to cancer metastasis. The implications of these findings are profound, potentially offering new avenues for treatment strategies to curb the spread of cancer in stress-induced conditions.
Young woman misdiagnosed with cancer
Read Lucy Younger’s harrowing journey of being misdiagnosed and dismissed by doctors before finally being diagnosed with a brain tumor. Despite being told she was ‘too young’ to have cancer, her persistence and advocacy for her own health ultimately led to a life-saving craniotomy.
New Microfluidic Device Revolutionizes Cell Therapy for Spinal Cord Injury Patients
MIT and Singapore-MIT Alliance for Research and Technology have developed a groundbreaking microfluidic device to enhance cell therapy for spinal cord injury patients. The device sorts and removes potentially harmful cells, improving safety and efficacy. It can process over 500 million cells per minute and is cost-effective for large-scale implementation, offering hope for improved treatment outcomes.
Former WWE Divas Champion Maryse Mizanin Shares Health Struggles on Instagram
Former WWE Divas champion and reality TV star, Maryse Mizanin, shares her recent health struggles on Instagram, revealing the removal of 11 borderline ovarian tumors and a scheduled total hysterectomy. She emphasizes the importance of advocating for one’s own health and the impact of finding a compassionate and attentive medical professional.
DELFI Diagnostics Announces Availability of Fragmentome-Based Cancer Monitoring Assay and Collaboration with Immunocore Holdings plc
DELFI Diagnostics, Inc. has announced the availability of the company’s fragmentome-based research use only (RUO) cancer monitoring assay, offering a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer. The company has also revealed a new research collaboration with Immunocore Holdings plc, focusing on exploring the use of the DELFI-TF cancer monitoring assay as an early predictor of benefit from treatment with ImmTAC-based therapies. DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible and deliver a new way to help detect cancer.
Early Signs of Breast Cancer in Dogs: What Pet Owners Need to Know
Learn about the early warning signs of breast cancer in dogs and how to reduce the risk of this disease. Dr. Anna Foreman shares valuable insights into the signs of mammary cancer in dogs and provides guidance on monitoring your pet’s health for potential indicators of the disease.